Results 281 to 290 of about 288,727 (306)

Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors

Cancer Communications, 2023
Hiroyuki Suzuki, Atsutaka Masuda, Takahiko Sakaue   +2 more
exaly  

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020

Bioorganic Chemistry, 2021
Xiaoxia Liang, Lizi Yin, Funeng Xu
exaly  

Resistance to Bruton Tyrosine Kinase Inhibitors

Hematology/Oncology Clinics of North America
Targeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire   +2 more sources

Tyrosine kinase inhibitors

Reactions Weekly
  +5 more sources

Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome

Integrative Cancer Therapies, 2020
Kate R Secombe, Ysabella Z A Van Sebille, Bronwen J Mayo   +2 more
exaly  

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska   +2 more
exaly  

Tyrosine kinase inhibitors

Reactions Weekly, 2020
openaire   +1 more source

Clinical pharmacokinetics of tyrosine kinase inhibitors

Cancer Treatment Reviews, 2009
Nielka P Van Erp, Hans Gelderblom, Henk-Jan Guchelaar   +2 more
exaly  

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Cancers, 2020
Charles Pottier, Margaux Fresnais, Guy Jerusalem   +2 more
exaly  

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?

Trends in Endocrinology and Metabolism, 2015
Athanasios Fountas, Agathocles Tsatsoulis   +1 more
exaly